|
KMID : 1038020170250040183
|
|
Translational and Clinical Pharmacology
2017 Volume.25 No. 4 p.183 ~ p.189
|
|
|
Development and validation of analytical method for the determination of radotinib in human plasma using liquid chromatography-tandem mass spectrometry
|
|
Seo Hyo-Bum
Cho Seun-Gil
Yoon Young-Ran
Yim Dong-Seok
|
|
|
Abstract
|
|
|
|
This study describes the development of an analytical method to determine radotinib levels in hu-man plasma using high performance liquid chromatography (HPLC) coupled with triple quadru-pole tandem mass spectrometry (MS/MS) for pharmacokinetic application. Plasma samples were sequentially processed by liquid-liquid extraction using methyl tert-butyl ether, evaporation, and reconstitution. Analytes were separated and analyzed using HPLC-MS/MS in selected reaction monitoring mode, monitoring the specific transitions of m/z 531 to 290 for radotinib and m/z 409 to 238 for amlodipine (internal standard). The HPLC-MS/MS analytical method was validated with respect to selectivity, linearity, sensitivity, accuracy, precision, recovery, and stability. Calibration curves were linear over a concentration range 5-3,000 ng/mL with correlation coefficients (r) > 0.998. The lower limit of quantification for radotinib in plasma was 5 ng/mL. The accuracy and pre-cision of the analytical method were acceptable within 15% at all quality control levels. This method was suitable to determine radotinib levels in human plasma because of its simplicity, selectivity, pre-cision, and accuracy.
|
|
|
KEYWORD
|
|
|
Radotinib (IY5511), HPLC-MS/MS, Human plasma, Method validation, Pharmacokinetic study
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|